{"entity":{"id":"fcrh5-expression","kind":"biomarker","name":"FcRH5 expression","aka":["FcRH5","FCRL5 expression","FcRH5-positive"],"tldr":"FcRH5 is a third myeloma surface target after BCMA and GPRC5D. Cevostamab, the FcRH5 x CD3 bispecific, is in phase 3; no approval or threshold exists yet.","summary":"FcRH5 is expressed on nearly all myeloma cells and gained on 1q21. Cevostamab is being tested in the phase 3 CAMMA 2 trial (NCT05535244) against standard combinations in relapsed or refractory myeloma after BCMA-directed therapy; trials enrol without an FcRH5 expression threshold. No regulator has approved an FcRH5-directed drug.","asOf":"2026-09-23","links":[{"label":"ClinicalTrials.gov NCT05535244 (CAMMA 2)","url":"https://clinicaltrials.gov/study/NCT05535244"}],"tags":["biomarker","surface-antigen","no-threshold"],"related":["bcma-expression","gprc5d-expression"],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["cevostamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"fcrh5","measurement":"ihc-score","scoringRule":{"text":"The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.","quote":"Cevostamab in relapsed or refractory multiple myeloma (CAMMA 2)","source":"https://clinicaltrials.gov/study/NCT05535244","sourceLabel":"ClinicalTrials.gov NCT05535244 (CAMMA 2)"},"thresholds":[],"definedBy":{"label":"CAMMA 2: cevostamab versus standard therapy in relapsed or refractory multiple myeloma (NCT05535244)","url":"https://clinicaltrials.gov/study/NCT05535244"},"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"FcRH5 is not something you will be tested for today; it is the target of cevostamab, an experimental bispecific antibody available in trials for myeloma that has come back after BCMA-directed treatment."},"route":"/biomarkers/fcrh5-expression/","neighbours":{"biomarker":[{"id":"bcma-expression","kind":"biomarker","name":"BCMA expression","route":"/biomarkers/bcma-expression/"},{"id":"gprc5d-expression","kind":"biomarker","name":"GPRC5D expression","route":"/biomarkers/gprc5d-expression/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/"}],"target":[{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/"}]}}